Free Trial

Kodiak Sciences Q2 2023 Earnings Report

Kodiak Sciences logo
$3.20 -0.32 (-9.09%)
As of 04:00 PM Eastern

Kodiak Sciences EPS Results

Actual EPS
-$1.53
Consensus EPS
-$1.23
Beat/Miss
Missed by -$0.30
One Year Ago EPS
N/A

Kodiak Sciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Kodiak Sciences Announcement Details

Quarter
Q2 2023
Time
N/A
Remove Ads

Kodiak Sciences Earnings Headlines

Kodiak Sciences (KOD) Expected to Announce Earnings on Thursday
30-year market phenomenon opens up overnight opportunity
Imagine this: When things worked out, you woke up, checked your account, and saw that you’ve made money overnight. Sounds like a dream, right? Well, what if that wasn’t a dream anymore? Earning while you sleep isn’t easy, and it definitely doesn’t happen overnight for most people.
Kodiak Sciences completes enrollment in GLOW2 Phase 3 trial
Kodiak Sciences granted orphan designation for tabirafusp alfa
See More Kodiak Sciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Kodiak Sciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Kodiak Sciences and other key companies, straight to your email.

About Kodiak Sciences

Kodiak Sciences (NASDAQ:KOD), a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

View Kodiak Sciences Profile

More Earnings Resources from MarketBeat